Voir la source de A New Unexplained Obscurity Into GDC-0449 Uncovered

TAS-102 is a novel antimetabolite being used for treatment of mCRC; clinical trials to evaluate its safety in patients with hepatic dysfunction are currently ongoing [10]. Mitomycin with capecitabine has also been employed in the palliative setting and does not require dose adjustments for hepatic impairment; however, the regimen is used infrequently [11]. With respect to our two cases, there was rapid deterioration of performance status in these individuals which was attributed to tumor progression. In these situations, an aggressive strategy with doublet based chemotherapy with or without a biologic should be considered. Rapidly progressive, life-threatening disease is a dire now-or-never scenario and if the decision is made to initiate treatment, it would not be appropriate to start with ��chemo-light�� such as 5-FU single agent. These cases illustrate two very different extreme outcomes [http://www.selleckchem.com/products/MS-275.html http://www.selleckchem.com/products/MS-275.html] that can be seen in patients with mCRC and concomitant liver dysfunction. While our first patient died within weeks of initiation of chemotherapy, our second patient achieved rapid improvement of symptoms and stabilization of disease for a significant period of time after diagnosis. This is consistent with the 3 other cases reported from Roswell Park Cancer Institute [6]. Outcomes for other patients were somewhat similar with initial response followed by progression later and exposure to multiple lines of chemotherapy approved for mCRC. These cases open the debate as to if [https://en.wikipedia.org/wiki/Quinapyramine Quinapyramine] and when systemic chemotherapy with or without biologics is an [http://www.selleckchem.com/products/GDC-0449.html GDC-0449 ic50] option for patients with mCRC and liver dysfunction. The decision is not straightforward but can be rationalized along the lines of a ��therapeutic triad�� incorporating the host, the drug, and the disease, which is usually at the back of our minds when we treat any patient with chemotherapy (Figure 3). Figure 3 ��Therapeutic triad�� of the host, the drug, and the disease: factors to consider when giving chemotherapy to patients. The most important part of the triad is the host (the patient). In our cases and others described in the literature, liver dysfunction was attributed to the metastases, and the patients were otherwise healthy and active with a good overall performance status prior to the diagnosis. If these patients already had been declining and had other significant comorbidities, we would have been less inclined to consider any treatment option at all. Both of these patients had palliative-intent surgery to begin with, which signifies overall reasonable clinical status of these patients. The second consideration is the underlying disease, in this case mCRC. Both of these tumors had no prior exposure to any chemotherapy or biologics; therefore, they were felt to be chemosensitive with potential for response and improvement in organ dysfunction [5]. This is noted in our second case and in other cases described in the literature.